<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811746</url>
  </required_header>
  <id_info>
    <org_study_id>#924</org_study_id>
    <nct_id>NCT00811746</nct_id>
  </id_info>
  <brief_title>Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?</brief_title>
  <official_title>Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if eszopiclone is as effective as ramelteon when&#xD;
      used as a pre-medication (sleeping pill) in sleep studies performed to diagnose and treat&#xD;
      sleep apnea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many Veterans suffer from sleep disordered breathing with a high prevalence of undiagnosed&#xD;
      obstructive sleep apnea. One test that can be effective in the diagnosis of sleep apnea is&#xD;
      the polysomnogram (PSG). Split-night PSG consists of a diagnostic phase in the first half of&#xD;
      the night and a continuous positive airway pressure titration (CPAP) in the second half of&#xD;
      the night. CPAP is the standard, most effective therapy for obstructive sleep apnea. Due to&#xD;
      the unfamiliar sleep environment of the laboratory and instrumentation that must be used&#xD;
      (application of electroencephalogram leads), patients are frequently not able to sleep&#xD;
      adequately. In these cases, the PSG must be repeated. Oral hypnotic agents are often used as&#xD;
      a pre-medication to increase the yield of PSG in an attempt to decrease the need for repeat&#xD;
      studies.&#xD;
&#xD;
      Numerous data is available on the effects of premedication with oral short-acting hypnotics&#xD;
      on PSG quality and efficacy of CPAP titration. In one study, eszopiclone, a nonbenzodiazepine&#xD;
      gaba-receptor agonist short-acting hypnotic, has been shown to improve PSG quality and CPAP&#xD;
      titration. Another short-acting hypnotic, ramelteon, was recently approved by FDA but the&#xD;
      effects of ramelteon in improving PSG quality and efficacy of CPAP titration are unclear. The&#xD;
      advantage of ramelteon over eszopiclone is the lack of drug dependency or abuse potential.&#xD;
      This study aims to evaluate the efficacy of ramelteon compared to eszopiclone when&#xD;
      administered prior to split-night PSG and CPAP titration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-usable and poor quality PSGs and CPAP intolerance</measure>
    <time_frame>The morning following the PSG</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rozerem (Ramelteon)</intervention_name>
    <description>8 mg taken orally 30 minutes before a split-night PSG</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ramelteon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lunesta (Eszopiclone)</intervention_name>
    <description>3 mg taken orally 30 minutes before the start of a split-night PSG</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Eszopiclone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Historical Controls</intervention_name>
    <description>Chart review matched for demographics and comorbidities of the study drug groups.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referred by VA Long Beach Sleep Clinic at their initial evaluation during outpatient&#xD;
             consultation for suspect obstructive sleep apnea.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sleep disorders other than obstructive sleep apnea&#xD;
&#xD;
          -  No prior PSG&#xD;
&#xD;
          -  Uncontrolled medical condition&#xD;
&#xD;
          -  Prior known adverse reaction to eszopiclone or ramelteon&#xD;
&#xD;
          -  Liver disfunction&#xD;
&#xD;
          -  Current alcohol abuser&#xD;
&#xD;
          -  Current illicit drug abuser&#xD;
&#xD;
          -  Alcohol consumption 12 hours prior to polysomnography&#xD;
&#xD;
          -  Decompensated psychiatric disorders&#xD;
&#xD;
          -  Severe dementia&#xD;
&#xD;
          -  Concomitant use of benzodiazepines, trazodone, narcotics, barbiturates or other&#xD;
             medications with sedative or hypnotic effects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine S. Sassoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Long Beach Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822-5201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.scire-lb.org/</url>
    <description>Southern California Institute for Research and Education Website</description>
  </link>
  <reference>
    <citation>Lettieri CJ, Quast TN, Eliasson AH, Andrada T. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep. 2008 Sep;31(9):1310-6.</citation>
    <PMID>18788656</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Catherine_Sassoon</investigator_full_name>
    <investigator_title>Staff Physician, Pricipal Investigator</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>eszopiclone</keyword>
  <keyword>ramelteon</keyword>
  <keyword>polysomnography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

